129 related articles for article (PubMed ID: 20349977)
1. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL
J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977
[TBL] [Abstract][Full Text] [Related]
2. Characterization of non-lipid autotaxin inhibitors.
Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of boronic acid based inhibitors of autotaxin.
Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
[TBL] [Abstract][Full Text] [Related]
4. Development of an activity-based probe for autotaxin.
Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
[TBL] [Abstract][Full Text] [Related]
7. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
9. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
10. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents.
Parrill AL; Baker DL
Anticancer Agents Med Chem; 2008 Dec; 8(8):917-23. PubMed ID: 19075574
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts.
Parrill AL; Baker DL
Expert Opin Ther Pat; 2010 Dec; 20(12):1619-25. PubMed ID: 21047298
[TBL] [Abstract][Full Text] [Related]
15. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
16. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
[TBL] [Abstract][Full Text] [Related]
17. Crystallization and preliminary X-ray crystallographic analysis of human autotaxin.
Inoue K; Tanaka N; Haga A; Yamasaki K; Umeda T; Kusakabe Y; Sakamoto Y; Nonaka T; Deyashiki Y; Nakamura KT
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Apr; 67(Pt 4):450-3. PubMed ID: 21505238
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidylmethanol is a pan lysophosphatidic acid receptor agonist and is produced by autotaxin in blood.
Endo T; Kano K; Motoki R; Hama K; Okudaira S; Ishida M; Ogiso H; Tanaka M; Matsuki N; Taguchi R; Kanai M; Shibasaki M; Arai H; Aoki J
J Biochem; 2009 Aug; 146(2):283-93. PubMed ID: 19416959
[TBL] [Abstract][Full Text] [Related]
19. Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells.
Li S; Zhang J
Biochem Biophys Res Commun; 2009 Jan; 378(2):264-8. PubMed ID: 19027716
[TBL] [Abstract][Full Text] [Related]
20. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
